格隆汇1月26日｜A股市场疫苗股集体走强，其中，华兰疫苗、金迪克20CM涨停，智飞生物涨超15%， 康乐卫士涨超13%，康希诺涨超12%，沃森生物涨超10%，康泰生物涨超7%，万泰生物涨近6%。 | 代码 | 名杯 | | 涨幅% ↓ | 总市值 | 年初至今涨幅% | | --- | --- | --- | --- | --- | --- | | 301207 | 华兰疫苗 | 1 | 20.00 | 140亿 | 25.28 | | 688670 | 金油克 | 李 | 19.98 | 31.14亿 | 24.96 | | 300122 | 智飞生物 | 1 | 15.39 | 477亿 | 5.67 | | 920575 | 康乐卫士 | 长 | 13.05 | 31.63亿 | 36.15 | | 688185 | 康布诺 | 1 | 12.38 | 192亿 | 23.63 | | 300142 | 沃森生物 | 1 | 10.78 | 230亿 | 32.24 | | 300601 | 康泰生物 | | 7.83 | 192亿 | 16.59 | | 603392 | 万泰生物 | 兼 | 5.9 ...

Core Viewpoint - The A-share market saw a significant rise in vaccine stocks due to the outbreak of the Nipah virus in West Bengal, India, which has a high mortality rate and no available vaccine [1] Group 1: Market Performance - Vaccine stocks such as Hualan Biological, Gendik, and Zhifei Biological experienced substantial gains, with Gendik hitting the 20% limit up, Zhifei Biological rising over 15%, and Kangle Health increasing by over 13% [1] - Other notable increases included CanSino Biologics up by over 12%, Watson Biotech by over 10%, and Kangtai Biological by over 7% [1] Group 2: Company Specifics - Gendik acknowledged awareness of the Nipah virus news but stated that the company does not have related products [1] - The total market capitalization of leading vaccine companies includes Zhifei Biological at 477 billion, Watson Biotech at 230 billion, and CanSino Biologics at 192 billion [2]

Meeting Overview - The first extraordinary general meeting of shareholders was held on January 21, 2026, at the company's conference room [2] - The meeting was presided over by Chairman Xu Biao and utilized a combination of on-site and online voting methods, complying with the Company Law and the Articles of Association [2][3] Attendance - All 9 current directors attended the meeting, with some participating via communication methods, and the board secretary along with all senior management also attended [3] Resolutions Passed - The meeting approved several resolutions regarding the non-public issuance of exchangeable corporate bonds, including: - Conditions for issuance [4] - Types of bonds to be issued [5] - Scale of issuance [5] - Types and terms of bonds [5] - Face value and issuance price [5] - Method of issuance [5] - Target of issuance [5] - Coupon rate and repayment methods [5] - Conversion price [5] - Guarantee arrangements [5] - Use of raised funds and special accounts [6] - Debt repayment security measures [6] - Proposed trading venues [6] - Other matters [6] - Validity period of the resolutions [6] - A resolution was also passed to authorize the board of directors and management to handle all matters related to the non-public issuance of exchangeable corporate bonds [6] Legal Verification - The meeting was witnessed by lawyers from Liaoning Hengxin Law Firm, confirming that the meeting's procedures, attendance, and voting were in compliance with legal and regulatory requirements [7]

辽宁恒信律师事务所 法律意见书 辽宁恒信律师事务所 关于辽宁成大股份有限公司2026年第一次临时股东会的 法律意见书 致：辽宁成大股份有限公司 辽宁恒信律师事务所（以下简称"本所"）接受辽宁成大股份有限公司（以 下简称"公司"）的委托，指派张贞东律师、于璇聪律师（以下简称"本所律师"） 出席公司2026年第一次临时股东会（以下简称"本次股东会"），并对本次股东 会的合法性进行见证。 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》《上市公司股东会规则》（以下简称"《股东会规则》"）等有 关法律、法规和规范性文件以及《辽宁成大股份有限公司章程》（以下简称"《公 司章程》"），本所律师审查了公司提供的如下文件： 1. 公司现行的《公司章程》； 2. 公司于2026年1月5日召开的第十一届董事会第十次（临时）会议的《董 事会决议》； 3. 公司于2026年1月6日刊登于《中国证券报》《上海证券报》《证券时报》 《证券日报》与上海证券交易所网站（http://www.sse.com.cn）的《辽宁成大股 份有限公司第十一届董事会第十次（临时）会议决议公告》；公司于2026年1月6 日 ...

证券代码：600739 证券简称：辽宁成大 公告编号：2026-009 辽宁成大股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 387 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 695,860,525 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 45.7107 | | 份总数的比例（%） | | (四) 表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次会议由董事会提议召开，由董事长徐飚先生主持，以记名投票方式表决。 会议采用现场投票和网络投票相结合的方式进行。会议的召开、表决方式符合《公 司法》及《公司章程》的规定。 (一) 股东会召开的时间：2026 年 1 月 21 日 (二) 股东会召开的地点：公司会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： ...

截至 2026 年 1 月 16 日，辽宁成大股份有限公司（以下简称"公司"） 控股股东韶关市高腾企业管理有限公司（以下简称"韶关高腾"）持有公司股份 247,772,048 股，占公司总股本比例为 16.20%。韶关高腾本次解质押股份数量为 15,040,000 股，剩余被质押股份数量为 89,030,000 股，剩余被质押股份占其所 持有公司股份比例为 35.93%，占公司总股本比例为 5.82%。 公司于 2026 年 1 月 19 日接到韶关高腾函告，获悉其所持有的公司部分股份 被解质押，具体事宜如下。 | 股东名称 | 韶关市高腾企业管理有限公司 | | --- | --- | | 本次解除质押股份 | 15,040,000 股 | | 占其所持股份比例 | 6.07% | | 占公司总股本比例 | 0.98% | | 解除质押时间 | 2026 年 1 月 16 日 | | 持股数量 | 247,772,048 股 | | 持股比例 | 16.20% | | 剩余被质押股份数量 | 89,030,000 股 | | 剩余被质押股份数量占其所持公司股份比例 | 35.93% | 1 | | | 证券 ...

辽宁成大公告称，截至2026年1月16日，控股股东韶关高腾持有公司股份247,772,048股，占总股本 16.20%。其本次解质押股份15,040,000股，占其所持股份比例6.07%，占公司总股本比例0.98%。剩余被 质押股份89,030,000股，占其所持公司股份比例35.93%，占公司总股本比例5.82%。若解质押股份后续 用于质押，公司将依规披露。 ...

Core Viewpoint - Liaoning Chengda Co., Ltd. has successfully completed the repayment of principal and interest for its second phase of ultra-short-term financing bonds due in 2026, indicating the company's financial stability and effective management of its debt obligations [1]. Group 1 - The company proposed to register an issuance limit of up to 5 billion RMB for ultra-short-term financing bonds, which was approved at the first extraordinary general meeting of shareholders in 2023 [1]. - The company issued 600 million RMB of ultra-short-term financing bonds on April 15, 2025, with a maturity of 270 days and an annual interest rate of 2.88% [1]. - The total amount raised from the bond issuance was fully received by the company on April 17, 2025 [1]. Group 2 - The second phase of the ultra-short-term financing bonds matured on January 12, 2026, and the company has completed the repayment of both principal and interest [1].

Investment Rating - The report indicates a stable investment outlook for the Japanese Encephalitis (JE) vaccine industry in China, driven by favorable national immunization policies and a concentrated market structure dominated by three major players [1][3]. Core Insights - The continuous optimization of the national immunization program (EPI) is identified as the key driver for the expansion of the JE vaccine market in China, with a significant increase in vaccination coverage and a reduction in disease incidence [3][5]. - The competitive landscape is stabilizing around three leading companies: Liaoning Chengda, Chengdu Biological Products Research Institute, and Kangtai Biological, which collectively hold over 90% market share [3][6]. - New entrants face high barriers to entry due to stringent regulatory requirements and the need for substantial investment in production capacity and distribution networks [4][6]. Summary by Sections National Immunization Policy and Market Dynamics - The JE vaccine market in China has expanded significantly since its inclusion in the EPI, with a reported market growth of approximately 2.8 billion yuan since 2007 due to increased vaccination rates [3]. - The demand for JE vaccines is expected to continue growing as the government aims to include more safe and effective vaccines in the EPI, enhancing the coverage of the population [3][5]. Competitive Landscape - The industry is characterized by a "three strong" market structure, where the leading companies have established significant technological and quality barriers, making it difficult for new entrants to disrupt the market [4][6]. - The focus of competition is shifting from product differentiation to a comprehensive competitive strategy that includes product technology upgrades, supply chain security, and regional penetration capabilities [7]. Vaccine Technology and Production - The JE vaccines in China are primarily categorized into live attenuated vaccines, inactivated vaccines, and mRNA vaccines, with live attenuated vaccines being the mainstay of the national immunization program [16][18]. - The production of JE vaccines relies heavily on standardized cell platforms, which ensure consistency and quality in vaccine manufacturing [30][32]. Vaccination Coverage and Public Health Impact - Vaccination coverage for JE vaccines has remained high, with rates stabilizing around 99% since 2010, indicating strong public health outcomes and effective immunization strategies [14][44]. - The report highlights the need for ongoing efforts to address vaccination gaps in high-risk populations, including rural areas and among migrant populations [44][28].

辽宁成大股份有限公司 2023 年 2 月 27 日，辽宁成大股份有限公司（以下简称"公司"）2023 年第 一次临时股东大会审议通过了《关于注册超短期融资券发行额度的议案》，公司 拟向中国银行间市场交易商协会申请注册金额不超过 50 亿元（含）人民币的超 短期融资券发行额度。公司于 2025 年 4 月 15 日在全国银行间市场发行规模为 6 亿元人民币的2025年度第二期超短期融资券，期限为270天，票面年利率为2.88%， 票面价格为 100 元/百元面值,募集资金于 2025 年 4 月 17 日全额到账。 2025 年度第二期超短期融资券于 2026 年 1 月 12 日到期，公司已完成该期 超短期融资券本息的兑付。 证券代码：600739 证券简称：辽宁成大 公告编号：2026-007 特此公告。 关于 2025 年度第二期超短期融资券到期兑付公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 辽宁成大股份有限公司董事会 2026 年 1 月 13 日 ...